NCT02269319View on ClinicalTrials.gov

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Bacterial Infections
Interventions
DRUG

MRX-I

Oral MRX-I 800mg given twice a day for 10 days

DRUG

Linezolid

Oral linezolid 600mg given twice a day for 10 days

Sponsors

Lead Sponsor

MicuRx
All Listed Sponsors
lead

MicuRx

INDUSTRY

NCT02269319 - MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection | Biotech Hunter | Biotech Hunter